GlassScriptPhysician profile
Janice R Rettig
NPI 1861772030
$4,041.05
in general payments reported to CMS, 2019-2025
17 companies · $813 in 2025
The $813 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $369 · 2022: $1,103 · 2023: $778 · 2024: $979 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,402 · Travel and Lodging: $135 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,402.40 |
| Travel and Lodging | $135.02 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $975.54 | 2021-2024 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Astrazeneca Pharmaceuticals LP | $844.55 | 2021-2025 | Farxiga, Lokelma, Wainua |
| Merck Sharp & Dohme LLC | $377.72 | 2022-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $317.84 | 2023-2025 | Amvuttra, Onpattro |
| Novartis Pharmaceuticals Corporation | $288.11 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $231.26 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.04 | 2021-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $159.78 | 2022-2025 | Eliquis |
| Abiomed | $145.46 | 2022-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $123.98 | 2022-2025 | Lifevest |
| Boston Scientific Corporation | $103.92 | 2023-2024 | Watchman Flx, Watchman Access System |
| Novo Nordisk INC | $84.67 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Kestra Medical Technology Services, INC. | $74.28 | 2024 | Assure Wcd |
| Bridgebio Pharma, INC. | $59.89 | 2025 | Attruby |
| Scpharmaceuticals INC. | $54.60 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $25.00 | 2023 | Injectafer |
| Janssen Pharmaceuticals, INC | $13.41 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Rettig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.